

ii) a polynucleotide encoding the polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 19, SEQ ID NO: 21, SEQ ID NO: 23; and

iii) a polynucleotide that hybridizes under moderately stringent conditions to the non-coding strand of the polynucleotide of (i) or (ii); said moderately stringent conditions comprising a final wash at 65° C in 2X SSC and 0.1%SDS,
said method comprising the steps of:

- a) contacting the phosphodiesterase polypeptide with a compound under conditions which permit binding between the compound and the phosphodiesterase polypeptide;
- b) detecting binding of the compound to the phosphodiesterase polypeptide; and
- c) identifying the compound as a specific binding partner of the phosphodiesterase polypeptide.

35. The method according to claim 34 wherein the specific binding partner modulates activity of the phosphodiesterase polypeptide.

36. The method according to claim 35 wherein the compound inhibits activity of the phosphodiesterase polypeptide.

37. The method according to claim 35 wherein the compound enhances activity of the phosphodiesterase polypeptide.

REMARKS

I. The Subject Matter of the Claims

During prosecution of the instant application, the Examiner issued a five-way restriction requirement. Accordingly, the cancellation of claims 1-33 and the introduction of new claims 34-37 in the instant amendment reflects the Applicant's election of group IV (corresponding to